I make a donation

CLOVIS-2

Pharmacogenetic cross-over trial on the response to different Clopidogrel loading doses depending on the presence of the CYP2C19*2 variant

Terminée

Remerciements de la Famille COLLET

Prix de Recherche Pr Jean-Philippe COLLET

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

objectif

Pharmacogenetic cross-over trial on the response to different Clopidogrel loading doses depending on the presence of the CYP2C19*2 variant

date de réalisation

2009

nombre de patients

109

nombre de centres participants

Monocentric (Pitié-Salpêtrière)

type de financement

Public (PHRC)

Référence

NCT00822666

Clopidogrel and Response Variability Investigation Study 2 (CLOVIS2)

Study Description

To evaluate the role of the genetic variant 2C19*2 on the pharmacodynamic response as assessed by optical aggregometry and on the pharmacokinetic response as assessed by measuring active metabolites following an oral administration of a loading dose of 300/900mg of clopidogrel in patients with established coronary artery disease.

source clinicaltrials.gov

Publications

CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients
Jean-Sébastien Hulot, Jean-Philippe Collet, Guillaume Cayla, Johanne Silvain, Frédérick Allanic, Anne Bellemain-Appaix, Stuart A Scott, Gilles Montalescot
Publicated in Circulation : Cardiovascular Interventions
High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)
Jean-Philippe Collet, Jean-Sébastien Hulot, Ghalia Anzaha, Ana Pena, Thomas Chastre, Claire Caron, Johanne Silvain, Guillaume Cayla, Anne Bellemain-Appaix, Jean-Baptiste Vignalou, Sophie Galier, Olivier Barthélémy, Farzin Beygui, Vanessa Gallois, Gilles Montalescot, CLOVIS-2 Investigators
Publicated in JACC : Cardiovascular Interventions

Autres études

BIO-TAVI

En cours

Correlation between the platelet reactivity, the von Willebrand factor and bleeding and thrombotic events occuring during the year following TAVI

ACORES-2

En cours

Evaluate the effect of RAS blockers discontinuation versus continuation on clinical course of patients infected with COVID-19.

AMUNDSEN

En cours

A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....